PD-1 as a potential target in cancer therapy.

Introduction

Multiple immunotherapeutic approaches to cancer treatment have been evaluated over the past several decades. Although the results of many of these early efforts have been disappointing, the ability to produce durable remissions of solid tumors with high-dose interleukin-2 (HD IL-2), interferon-α, and vaccines has nevertheless provided evidence of immunotherapy's potential 1 – 3 . Recent data have provided a clearer understanding of the factors that limit an antitumor immune response, leading to the development of various agents targeting immune costimulatory and inhibitory (“checkpoint”) pathways. One of the key checkpoint molecules that mediates tumor-induced immune suppression is programmed death-1 (PD-1).

Traditional costimulation is delivered by the signaling of antigen-presenting cell (APC) CD80/86 through T-cell CD28, the so-called “second signal” required for T-cell activation. In addition to CD28, other immune costimulatory molecules include inducible costimulator 4 , CD137 (also known as 4-1BB), and OX40 5 . Conversely, several negative regulatory checkpoint molecules function to prevent, or “check,” overstimulation of immune responses and contribute to the maintenance of immune tolerance to self-antigens 6 . These molecules include cytotoxic T-lymphocyte antigen-4 (CTLA-4) as well as the PD-1 receptor and its ligands. CTLA-4 acts as a signal dampener that acts largely within the lymph nodes to regulate the magnitude of early activation of naïve and memory T cells. PD-1, by contrast, is induced on T cells after activation in response to inflammatory signals and limits T-cell function in various peripheral tissues, largely in the context of infection or tumor progression 7 . As the T-cell response builds, these negative regulatory molecules are induced, limiting the magnitude and duration of the response to prevent healthy tissue damage.

Tumors are capable of exploiting the homeostatic mechanisms regulated by these checkpoint molecules. They can overwhelm the immune system via multiple strategies, including alterations in antigen expression, interference with T-cell priming, and a spectrum of effects referred to as “immune editing,” whereby tumors manipulate their microenvironment during development to escape immune detection and eradication 8 . Limiting antitumor T-cell responses via exploitation of checkpoint pathways (such as those involving CTLA-4 or PD-1) serves to prevent significant tumor destruction and leads to an equilibrium between the tumor and immune system that typically progresses to tumor escape. New immunotherapies for cancer focus on shifting the balance from a pro-tumor to an antitumor microenvironment, thus allowing the immune system to mount an effective antitumor response; consequently, negative regulatory pathways are key targets. The anti–CTLA-4 monoclonal antibody (mAb) ipilimumab improved survival in a phase 3 trial in patients with metastatic melanoma (MEL) 9 and was subsequently approved by the United States Food and Drug Administration for the treatment of patients with advanced MEL. A recent report of an early-stage trial has provided preliminary evidence of activity of ipilimumab in patients with castrate-resistant prostate cancer (CRPC) 10 . The fully human anti–PD-1 mAb BMS-936558/MDX-1106/ONO-4538 (nivolumab), tested in renal cell cancer (RCC), MEL, CRPC, non–small cell lung cancer (NSCLC), and colorectal cancer (CRC), has demonstrated antitumor activity in phase 1/1b studies 11 . The humanized anti–PD-1 antibody MK-3945 (lambrolizumab) has also demonstrated antitumor activity in patients with solid cancers in a phase 1 study 12 . CT-011 (pidilizumab), a humanized anti–PD-1 antibody, has been evaluated in multiple hematologic malignancies, demonstrating potential clinical activity in patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Hodgkin's lymphoma, multiple myeloma, and acute myeloid leukemia 13 . Finally, the anti–PD ligand 1 (PD-L1) mAb BMS-936559 has shown preliminary antitumor activity in various solid cancers 14 . PD-1 pathway–targeted agents in development are summarized in Table 1 . This review examines the role of the PD-1 negative regulatory pathway in antitumor immune responses and outlines the rationale for targeting PD-1 and PD-L1 in the treatment of patients with cancer.

Role of the PD-1 Pathway in the Immune Response

PD-1 (CD279), a member of the B7-CD28 family 15 , is a cell surface coinhibitory receptor expressed on T cells, B cells, monocytes, and natural killer T cells, following activation 16 . PD-1 has two known ligands: PD-L1 (B7-H1) 17 and PD-L2 (B7-DC) 18 , which have distinct expression profiles. Both ligands are expressed on APCs, including dendritic cells (DCs); in addition, PD-L1, thought to be the principal mediator of PD-1-dependent immunosuppression 19 , is expressed on some nonhematopoietic cells. Binding of PD-L1 or PD-L2 to PD-1 inhibits T-cell receptor signaling and downregulates the expression of certain antiapoptotic molecules (including B-cell lymphoma-extra large [Bcl-xL]) and proinflammatory cytokines 16 . The interaction of PD-1 with its ligands also affects the cell cycle, preventing progression through G1 phase by increasing expression levels of p15 and suppressing transcription of SKP2 , a component of the ubiquitin ligase responsible for degrading p27 20 . PD-L1 itself has also been observed to serve as an antiapoptotic factor on tumor cells 21 . Interestingly, PD-L1 expressed on APCs can also bind T-cell CD80, which curtails T-cell activation and cytokine production. The PD-1 pathway is an important regulator of the induction and maintenance of peripheral tolerance (and tolerance to malignant “self” cells within the tumor microenvironment) 22 , 23 , by upholding a balance between T-cell activation and the protection of healthy tissues from immune-mediated damage.

The critical role of the PD-1 pathway in blunting T-cell responses was first demonstrated by the various autoimmune phenotypes observed in PD-1 knockout mice 16 . In addition, PD-L1 expression on nonhematopoietic cells was shown to inhibit immune-mediated tissue damage 21 , 24 . The PD-1/PD-L1 pathway also participates in the regulation of immunity to chronic infections. Persistent T-cell activation in the setting of chronic infection produces sustained, high-level PD-1 expression and results in functionally exhausted T cells. Such T cells are unable to proliferate and destroy invading microorganisms, thus allowing infections to persist; however, this inactivity of T cells also reduces collateral immune-related damage to host cells 25 . Cancers exploit multiple immunoregulatory pathways to evade elimination by infiltrating, activated tumor-specific T cells, including the production of immunosuppressive cytokines (transforming growth factor-β [TGF-β], interleukin-10 [IL-10]), the expression of immunosuppressive enzymes (indoleamine-2,3-dioxygenase), and the conversion of “normal” APCs and T cells to immunosuppressive cell populations (e.g., regulatory T cells) 26 . Similarly, tumor upregulation of PD-L1 expression, commonly induced by infiltrating T-cell release of interferon-γ (IFN-γ) 27 , leads to inactivation of T cells expressing PD-1, further enabling tumor cell evasion of immune destruction (Fig. 1 ).

Role of the PD-1 Pathway in Cancer

Gajewski and colleagues have recently observed that certain tumors exhibit an “inflammatory” gene signature, suggesting the existence of an ongoing immune response; moreover, patients with “inflamed” tumors appear to respond better to immunotherapy. Intriguingly (and perhaps counter-intuitively), “inflamed” tumors contained higher expression levels of the immunosuppressive molecules PD-L1, FoxP3 (the transcription factor controlling regulatory T-cell [Treg] development) and indoleamine-2,3-dioxygenase (an enzyme critically involved in peripheral tolerance) 28 . The PD-1 pathway, therefore, may have a key role in the interaction of tumor cells with the host immune response, and tumor cell PD-L1 expression may serve as a mechanism of adaptive immune resistance.

Expression of PD-1 by tumor-infiltrating lymphocytes (TILs) is associated with impaired effector function (cytokine production and cytotoxic efficacy against tumor cells) and/or poor outcome in several tumor types 29 – 32 . Moreover, a variety of tumors, including RCC, MEL, as well as stomach, breast, ovarian, pancreatic, and lung cancers, have been shown to express PD-L1, potentially contributing to immune suppression and evasion 33 . Of note, PD-L1 expression on tumor cells has been shown to correlate with poor prognosis in patients with RCC (Fig. 2 ) 34 , MEL, and breast, pancreatic, stomach, bladder, lung, liver, and ovarian cancers (Table 2 ) 33 , 35 – 38 . However, a recent report has shown that not all tumor PD-L1 expression confers a worse prognosis 27 . In this study, patients with PD-L1 + MEL survived significantly longer than patients with PD-L1 − MEL, spurring investigators to hypothesize that TILs may actually prompt their own inhibition by secreting cytokines (such as IFN-γ) that drive tumor PD-L1 expression. However, because of the significant number of patients who received subsequent immune-based therapies, care must be taken interpreting these data. It is, however, possible that induction of the PD-L1/PD-1 pathway represents a mechanism of adaptive resistance exerted by tumors infiltrated by effector T cells, and is therefore a marker of an ongoing antitumor immune response. Similarly, PD-L2 has been observed to be upregulated in a subset of human tumors and has occasionally been linked to poor outcome 39 . Consequently, therapies that block the PD-1 pathway may unleash antitumor immunity and be particularly beneficial to patients with PD-L + tumors.

Ahmadzadeh and colleagues showed that PD-1 expression on TILs in MEL lesions was significantly higher than expression on T cells isolated from the peripheral blood (PB) or noncancerous tissue from the same patients or healthy donors 31 . In this study, PD-1 + TILs had impaired effector function, as measured by IFN-γ secretion, indicating that PD-1 expression on TILs limits their capacity to mount an effective immune response. Patients with MEL also have higher levels of PD-1 expression on TILs than on PB lymphocytes 40 . In addition, blockade of the PD-1/PD-L1 pathway increased IFN-γ secretion by T cells in response to stimulation by antigen-loaded DCs. Overall, these findings suggest that inhibition of the PD-1/PD-L1 pathway can restore effector functions of exhausted T cells, which may translate into improved antitumor immune responses. Thus, the PD-1/PD-L1 pathway represents a logical target for cancer immunotherapy.

Preclinical Studies of PD-1 Blockade

Blockade of either PD-1 or its ligands has shown consistent immune-potentiating effects in a range of preclinical models. Antibodies against PD-1 or PD-L1 can enhance or restore T-cell effector function, including cytolytic activity against tumor cells 40 – 42 . Moreover, PD-L1 blockade promoted infiltration of tumor-reactive CD8+ T cells into established tumors in a mouse model of pancreatic cancer 43 , while PD-L2 blockade decreased the numbers of tumor-infiltrating regulatory T cells 44 . PD-1 blockade inhibited the metastatic spread of MEL and colon cancer cells in mice 45 . Experiments in mice lacking PD-1 showed that hematogenous tumor spread was inhibited via several T-cell potentiating mechanisms, including enhanced induction of effector T cells in the spleen, augmented homing of these cells to tumor sites, and improved T-cell proliferation and cytotoxicity 45 . Several preclinical studies have shown that PD-1 or PD-L1 blockade improves the immune response to, and/or efficacy of, other immunotherapies, including anti–CTLA-4 mAbs 41 – 43 , 46 . PD-L1 inhibition was also synergistic with chemotherapy in a mouse model of pancreatic cancer 43 . These observations have important implications for the development of potential combination treatment strategies for patients with cancer.

Clinical Studies Investigating PD-1/PD-L1 Blockade

Because of the varied negative signals resulting from interactions between PD-1/PD-L1/PD-L2 and PD-L1/CD80, there are opportunities to target this checkpoint pathway from two directions: PD-1 blockade inhibits negative signaling induced by PD-L1 and PD-L2 ligation, whereas PD-L1 blockade inhibits negative signaling via PD-1 and CD80. MAbs that target these interactions are being evaluated in clinical studies and hold promise as an important immunotherapeutic approach in various malignancies. Data from clinical trials targeting the interactions between PD-1 and its ligands have recently become available.

PD-1 Blockade with Anti–PD-1 Antibodies

Nivolumab

The first phase 1 trial of varying doses (0.3–10 mg/kg) of nivolumab, a fully human IgG4 anti–PD-1-blocking antibody, in 39 patients with advanced MEL, CRC, CRPC, NSCLC, or RCC was reported in 2010 19 . One complete response (CR) (CRC 3 mg/kg) (21+ months at last follow-up) and two partial responses (PRs) (RCC and MEL [both 10 mg/kg]) were observed. No maximum tolerated dose (MTD) was identified. Most adverse events (AEs) reported for nivolumab were immune-related, consistent with the mechanism of action of anti–PD-1 antibodies. Flow cytometric analysis showed sustained occupancy of the majority of PD-1 molecules on circulating T cells isolated from patient plasma samples for ≥3 months following a single dose of nivolumab. In an expansion cohort at the 10-mg/kg dose level, responses were seen in patients with MEL and RCC without increased toxicity. One patient with RCC who had received several prior therapies achieved a PR that lasted 16+ months despite receiving only three nivolumab infusions. Additionally, two patients (NSCLC, MEL) achieved significant regression of metastatic lesions that did not meet PR criteria 19 . Follow-up of three patients from this study has demonstrated long-term responses after discontinuation of therapy 47 .

The activity seen in the initial study prompted an exploration of a biweekly schedule of nivolumab in a separate phase 1 trial 11 , 48 . Interim data from 304 patients with RCC, MEL, CRPC, NSCLC, or CRC who received 0.1 mg/kg to 10 mg/kg nivolumab every 2 weeks in 8-week cycles have recently been reported. Patients received treatment (≤12 cycles) until they experienced CR or progressive disease. Of 294 response-evaluable patients, there were objective responses (ORs) in 20/122 patients with NSCLC, 33/106 patients with MEL, and 10/34 patients with RCC. No ORs were noted in patients with CRPC or CRC. At last follow-up, 28 patients to date have had responses lasting ≥1 year. Stable disease (SD) lasting 24+ weeks was observed in an additional six evaluable patients with MEL, 11 with NSCLC, and nine with RCC. Additional patients with each disease experienced tumor responses to nivolumab according to immune-related response criteria; one pattern is typified by an initial increase and then decrease in tumor size (Fig. 3 ). Antitumor activity was observed at 1- to 10-mg/kg dose levels; some patients appeared to continue to exhibit tumor response beyond 96 weeks, the protocol-defined treatment stoppage point. The most common treatment-related AEs included fatigue, rash, nausea, diarrhea, decreased appetite, and pruritus. Grade 3/4 treatment-related AEs occurred in 15% of patients, and there were three deaths, all attributed to pulmonary toxicity. Drug-related AEs of special interest (AEOSIs, AEs with potentially immune-related etiology) included vitiligo, pneumonitis, hepatitis, colitis, thyroiditis, and hypophysitis. Should this preliminary efficacy and relatively favorable toxicity profile be confirmed in future trials, PD-1 pathway blockade may be an approach that can produce a durable benefit with fewer toxicities than with other immunotherapies (e.g., HD IL-2 or ipilimumab). Nivolumab is currently being evaluated in several ongoing clinical trials of patients with RCC, MEL, and various other malignancies ( http://clinicaltrials.gov ).

Pidilizumab

The humanized, anti–PD-1 mAb pidilizumab was evaluated in a phase 1 clinical trial of patients with advanced hematologic malignancies 13 . Seventeen patients received escalating doses of pidilizumab ranging from 0.2 to 6 mg/kg. Treatment with pidilizumab generally was well tolerated, and no MTD was defined. Only one patient reported toxicity, specifically weakness, and flushing, which were possibly treatment related. Clinical benefit was observed in 33% of patients. An apparent response to treatment was observed in six patients, including one CR, four SD, and one mixed response; the CR was maintained for ≥68 weeks. Sustained elevation in PB CD4 + lymphocyte numbers was observed up to 21 days following treatment with pidilizumab 13 . The activity of pidilizumab in solid tumors is now being explored ( http://clinicaltrials.gov ).

Lambrolizumab

Patnaik and colleagues reported the results of a small, open-label dose-escalation study examining lambrolizumab, a humanized IgG4 mAb against PD-1 12 . Cohorts of three to six patients with various advanced solid tumors were treated with 1–10 mg/kg initially and then additional doses every 2 weeks. No MTD was identified, and there were no grade ≥3 drug-related AEs; one patient developed pneumonitis, which was treated with corticosteroids. Two patients with MEL treated for 6+ months had PRs, and there was an unconfirmed PR in a patient with squamous NSCLC. In the MEL expansion cohort treated with 10 mg/kg, one unconfirmed CR, three unconfirmed PRs, and five grade 3/4 AEs were reported ( NCT01295827 ) 12 . Additional interim data on 85 evaluable patients were recently presented at the Society for Melanoma Research Congress 49 , Forty-three patients (51%) experienced ORs, including eight CRs. 27 patients had previously been treated with ipilimumab and 11 of these (41%) had ORs. Seven treatment-related grade 3/4 AEs with potentially immune-mediated causes were reported. There were three instances of grade 1/2 pneumonitis; one patient died of myocardial infarction while being treated for pneumonitis/pneumonia. Common AEs included arthralgia, cough, diarrhea, fatigue, fever, nausea, pruritus, and rash.

Patterns of response to PD-1 blockade

While a subset of melanoma and lung cancer patients treated with PD-1-pathway–targeted agents have experienced encouraging ORs, fewer have experienced SD. It is possible that the response to PD-1 pathway blockade is “all or nothing.” In comparison, while only a small percentage of patients treated with ipilimumab achieve ORs, this agent improved median OS in phase 3 trials, suggesting a clinical benefit in patients who did not meet response criteria 9 , 50 . It is possible that PD-1-pathway–directed agents may impart a survival benefit only to those patients on the “tail” of the survival curve. Whether these agents will improve median OS in unselected patients will be determined by ongoing, randomized phase 3 trials.

It should be noted that select responding patients who discontinued PD-1 antibody therapy subsequently demonstrated disease progression, suggesting that the optimal duration of anti–PD-1 agent dosing may vary from patient to patient. However, some patients who progressed after discontinuation of anti–PD-1 therapy have demonstrated durable responses after retreatment 47 . The optimal duration of PD-1-pathway–targeted agent treatment is still being determined; if shorter treatment durations are proven efficacious, this approach would be more cost-effective. The ultimate benefit of immunotherapeutics (e.g., IL-2, ipilimumab) is their ability to produce remissions that are durable when therapy is discontinued. Although this has been observed in select patients treated with anti–PD-1 agents, the percentage of patients who achieve durable remissions remains to be determined. Nonetheless, the potential benefits for patients who experience “treatment-free survival” include decreased treatment-associated toxicity, improved quality of life, and decreased cost to the healthcare system. While this endpoint is not currently standard for approving therapies, its value to the patient merits consideration in future studies.

PD-1 Blockade with PD-1 Ligand-targeted Agents

BMS-936559

Interim data from a phase 1 trial ( NCT00729664 ) of BMS-936559, an anti–PD-L1 mAb, have recently been disclosed 14 . As of 24 February 2012, 207 patients (with NSCLC, MEL, CRC, RCC, and ovarian, pancreatic, or breast cancer) had received BMS-936559 (at escalating doses ranging from 0.3 to 10 mg/kg) every 2 weeks in 6-week cycles. This continued for 16 cycles or until progressive disease or CR; the MTD was not identified. In the evaluable population, ORs were observed in patients with MEL (9/52), RCC (2/17), NSCLC (5/49), and ovarian cancer (1/17). In the 16 patients with ≥1 year of follow-up, responses in half lasted for ≥1 year. SD (≥24 weeks) was observed in 14 patients with MEL, six patients with NSCLC, three patients with ovarian cancer, and seven patients with RCC. Most AEs were low grade; the most common treatment-related AEs included fatigue, diarrhea, infusion reactions, rash, arthralgia, headache, nausea, and pruritus. Grade 3/4 treatment-related toxicities occurred in 9% of patients. Thirty-nine percent of patients experienced AEOSIs, including rash, hepatitis, hypothyroidism, and one case each of diabetes mellitus, endophthalmitis, sarcoidosis, and myasthenia gravis. The data collected to date demonstrate that BMS-936559 has a relatively good safety profile and can induce durable responses in patients with MEL, NSCLC, and RCC.

Other agents

Genentech and Roche are evaluating a mAb targeting PD-L1 (RG7446/MPDL3280A), and Amplimmune and GlaxoSmithKline have partnered in the development of a PD-L2/IgG1 fusion protein (AMP-224) that blocks PD-1 signaling. More recently, MedImmune announced that it would pursue development of the anti–PD-L1 mAb MEDI4736 51 . All three of these compounds are currently in phase 1 testing ( http://clinicaltrials.gov ).

Targeting PD-1 versus PD-L1

Without a randomized, head-to-head trial of these drugs, no conclusive statements can be made regarding the comparative safety and activity of agents targeting PD-1 versus those targeting PD-L1. It appears, however, that targeting only PD-L1 may be accompanied by less toxicity, but also may be less effective than targeting PD-1 and thus blocking signaling via both PD-L1 and PD-L2.

Differences from anti–CTLA-4 antibodies

The anti–PD-1 data we currently have are from phase 1 trials, and no randomized, head-to-head studies of anti–PD-1 and anti–CTLA-4 antibodies have been completed. However, the existence of these agents in the same immunotherapeutic category will no doubt prompt comparisons. Both PD-1 and CTLA-4 are checkpoint molecules; however, they participate in different phases of the immune response. Murine experiments suggest that CTLA-4 is centrally involved in the development of tolerance and the prevention of autoimmunity, while the role of PD-1 is to prevent bystander tissue damage at sites of chronic infection and inflammation 52 – 54 . Additionally, given the body of data on PD-L1 and PD-1 as potential prognostic and predictive biomarkers, it seems that this pathway may be more important in the tumor microenvironment. Preclinical data 46 suggest that the combination of inhibitors of PD-1 and CTLA-4 may present a promising approach, which is currently being explored in the clinical setting [ NCT01454102 , NCT01024231 ].

Future Directions

Predictive biomarker development

The correlation between tumor PD-L1 expression and prognosis supports the hypothesis that this molecule may serve as a predictive biomarker. Although immune infiltration of antitumor lymphocytes leading to PD-L1 upregulation might establish a scenario predictive of benefit for any effective immunotherapy, this is particularly true of agents targeting the PD-1 pathway. As mentioned previously, expression of PD-1 by TILs is associated with poor prognosis in multiple cancers 29 , 32 . In patients with RCC, the presence of PD-1 + TILs was associated with more aggressive tumors and shortened survival 29 . In addition, patients with PD-1 + TILs were more likely than patients without PD-1 + TILs to have larger tumors, tumors of higher nuclear grade, advanced tumor node-metastasis stage, coagulative tumor necrosis, and sarcomatoid differentiation. In RCC and other cancers, tumor expression of PD-L1 is also associated with poor prognosis and more aggressive disease 33 , 34 . However, the significance of PD-L1 expression in the context of active immunotherapy, particularly PD-1/PD-L1 pathway blockade, is less clear. Given that tumor PD-L1 expression is induced by T-cell expression of IFN-γ, it may signify an effort by the tumor to evade an ongoing immune response. Therefore, blockade of the PD-1/PD-L1 pathway with an anti–PD-1 or anti–PD-L1 antibody may enable the unmasking of antitumor immunity patients with PD-L1 + tumors. Preliminary data suggesting that tumor PD-L1 expression could be a predictive biomarker of response to nivolumab 19 were later supported by an observation that 0/17 nivolumab-treated patients with PD-L1 − tumors experienced ORs, whereas 9/25 patients with PD-L1 + tumors (36%) achieved ORs ( P = 0.006). If these data are confirmed, PD-L1 positivity may be a way to identify and enrich the population of patients who benefit from PD-1 pathway–targeted therapy. Further evaluation of PD-L1 as a potential predictive marker is warranted.

Opportunities for combination therapy

Even at this stage of PD-1–targeted agent development, it is important to consider opportunities for combination therapy. Given the observation that multiple factors can induce PD-L1 expression, it may be feasible to treat patients with these molecules (e.g., IFN-α, -β, and -γ 16 ; cisplatin 55 ) to induce PD-L1 expression in the tumor microenvironment and expand the population of patients who might benefit from treatment with PD-1-pathway–directed agents. In addition, tumors can evade detection and destruction by manipulating the immune system: downregulating costimulatory molecules on tumor cells, increasing expression of immunosuppressive molecules, and dysregulating T cells and APCs. Therefore, the implementation of rational, multiagent treatments that target distinct pathways may circumvent these tumor survival strategies.

Dual checkpoint blockade

The combination of CTLA-4 and PD-1 blockade may also enable more persistent immune activation while avoiding the major toxicities associated with HD IL-2. Hypothetically, combining two agents that target T-cell activation at different stages of the immune response will be a more potent anticancer treatment than therapy with each agent alone. Ipilimumab removes a physiological brake on T cells during activation, whereas anti–PD-1 removes a brake on activation during T-cell effector function. This combination may also overcome resistance to CTLA-4 blockade mediated by tumor PD-L1 expression or resistance to PD-1 blockade mediated by T-cell downregulation through the coexpression of CTLA-4. A phase 1 trial of nivolumab and ipilimumab in patients with MEL is ongoing ( NCT01024231 ). Another potential checkpoint combination therapy might include blockade of PD-1 and LAG-3, a molecule also involved in the regulation of T-cell activation. Combination therapy in mice has shown impressive activity 56 .

Targeted therapy combinations

The combination of agents that block immune downregulation with genetic or cell-targeted therapies may prove particularly effective in select patients. Following this line of thought, pidilizumab is being tested in combination with rituximab, an anti-CD20 antibody, in a phase 2 trial of patients with relapsed follicular lymphoma ( NCT00904722 ). The combination of PD-1–targeted therapy with agents effective against genetic mutations may also demonstrate activity. Trials examining vemurafenib, an inhibitor of B-raf enzymes with the V600E mutation, and other BRAF and epidermal growth factor receptor–targeted agents, in combination with PD-1 pathway inhibitors are under way ( NCT01454102 , NCT01656642 ). Various chemotherapies are also being evaluated in combination with anti–PD-1 agents ( NCT00890305 , NCT01454102 ).

T-cell stimulating agent combinations

IL-2 is a cytokine that supports T-cell survival and proliferation. The combination of HD IL-2 and ipilimumab has demonstrated manageable toxicity and impressive efficacy (CR rate of 17%) in patients with advanced MEL 57 . Thus, it is conceivable that the combination of HD IL-2, to induce T-cell expansion, and PD-1 blockade, to eliminate tumor-induced immune suppression, might prove equally or more efficacious in select patients.

Vaccine combinations

The PD-1/PD-L1 pathway may play an important role in blunting immune response to tumor vaccines. Study findings suggest that stimulation with dendritic/tumor fusion cells increases T-cell expression of PD-1, which may blunt the host response to vaccination 58 . In ex vivo studies, stimulation of T cells with a DC/tumor fusion vaccine in the presence of PD-1 blockade resulted in increased cytokine production, decreased Tregs, and enhanced tumor killing 58 . As such, combining DC-based tumor vaccines with PD-1 blockade may be an effective means of enhancing immunologic and clinical response to vaccination. Interestingly, two trials evaluating the efficacy of nivolumab in combination with multipeptide melanoma vaccines are ongoing ( NCT01176474 , NCT01176461 ). Thus far, confirmed PRs have been reported in patients with unresectable melanoma at each of the treating dose levels (two at 1 mg/kg, four at 3 mg/kg, and one at 10 mg/kg), and the most common drug-related AEs are low-grade injection site reactions and nausea/vomiting 59 . Pidilizumab is being tested in combination with DC fusion vaccines in patients with multiple myeloma after stem cell transplantation ( NCT01067287 ), patients with RCC ( NCT01441765 ), and patients with acute myeloid leukemia ( NCT01096602 ).

VEGFR tyrosine kinase inhibitor (TKI) combinations

The anti–CTLA-4 mAb tremelimumab administered with the vascular endothelial growth factor receptor (VEGFR) TKI sunitinib produced PRs in 9/21 evaluable patients with RCC, but was associated with acute renal toxicity, which the authors proposed might be immune related 60 . It is conceivable that combinations involving VEGFR TKIs with PD-1/PD-L1 pathway blockade may be better tolerated. Thus, an ongoing trial is assessing the safety and tolerability of nivolumab when administered with sunitinib or pazopanib in patients with RCC ( NCT01472081 ) 61 .

VEGF-targeted agent combinations

There is evidence that VEGF decreases DC function 62 , and by extension, antigen presentation and T-cell activation. Concurrently restoring DC and T-cell functionality may improve the antitumor T-cell response and lead to improved clinical activity. As proof-of-concept, Hodi and colleagues have observed durable PRs in patients with MEL treated with a combination of ipilimumab and the anti–VEGF-A antibody bevacizumab 63 . Trials evaluating the combination of nivolumab ( NCT01454102 ) or ipilimumab ( NCT00790010 ) with bevacizumab are ongoing ( http://clinicaltrials.gov ).

Various benefits and drawbacks accompany the use of broad spectrum versus more specific VEGF inhibitors. Broad-spectrum agents are indeed pleiotropic and, among various “off-target effects” can impact immune system function. For instance, murine experiments have shown that sunitinib can decrease Treg populations 64 ; other TKIs are associated with immune system-potentiating effects 65 . If the pleiotropic effects of a given VEGFR TKI have a net positive effect on the immune system and are not overwhelmingly detrimental to other physiological processes, it may indeed be worth exploring in combination with anti–PD-1-pathway–directed agents. In contrast, VEGF-targeted agents like bevacizumab and VEGF-trap are more specific in their inhibition, but are not typically accompanied by immune-potentiating effects. As high levels of VEGF are associated with impeded dendritic cell function, lowering environmental VEGF concentrations might benefit this aspect of the antitumor immune response. In recent phase 3 studies, bevacizumab administered in combination with IFNα was more effective than IFNα alone 66 , suggesting that combination therapy of PD-1–directed agents and VEGF-binding antibodies merits future study.

Conclusions

Although first-generation immunotherapies were of limited efficacy, they provided proof-of-concept that, in some patients, the immune balance in the tumor could be shifted in favor of tumor elimination. Expanding knowledge and understanding of the immune system's role in cancer has revealed multiple mechanisms by which tumors evade immune destruction. In particular, negative regulatory pathways involved in the T-cell-mediated response, including interaction of PD-1 and PD-L1, are being investigated to determine their role in tumor development. Various solid tumors express PD-L1, often associated with poor prognosis, whereas TILs from these patients express PD-1 and have impaired antitumor functionality. Preclinical proof-of-concept for PD-1/PD-L1 blockade has been demonstrated by many studies: improvements in various antitumor T-cell functions have been observed. Several PD-1 and PD-L1-blocking mAbs have now completed early clinical development with encouraging activity and safety. The potential for these agents in the treatment of patients with advanced cancers, including their incorporation into combination regimens (e.g., PD-1- plus CTLA-4-blocking antibodies), is significant, and further data are eagerly awaited.

Supported in part by the DF/HCC Kidney Cancer SPORE: P50 CA101942-01. Professional medical writing and editorial assistance was provided by Cailin Moira Wilke, PhD, at StemScientific and was funded by Bristol-Myers Squibb.

Conflict of Interest

Dr. Atkins has served as a consultant for BMS, Prometheus, and Merck; he also is a member of the Scientific Advisory Board for CoStim Pharmaceuticals Inc., and cCam Biotherapeutics. Dr. McDermott has participated in a BMS Advisory Board and has served as a consultant for BMS, Genentech, Prometheus, Pfizer, and Curetech.

References

Petrella T Quirt I Verma S Haynes AE Charette M Bak K Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review Cancer Treat. Rev 2007 33 484 496 17562357 10.1016/j.ctrv.2007.04.003

Canil C Hotte S Mayhew LA Waldron TS Winquist E Interferon-alfa in the treatment of patients with inoperable locally advanced or metastatic renal cell carcinoma: a systematic review Can. Urol. Assoc. J 2010 4 201 208 20514286 10.5489/cuaj.853 PMC2874597

Kantoff PW Higano CS Shore ND Berger ER Small EJ Penson DF Sipuleucel-T immunotherapy for castration-resistant prostate cancer N. Engl. J. Med 2010 363 411 422 20818862 10.1056/NEJMoa1001294

Hutloff A Dittrich AM Beier KC Eljaschewitsch B Kraft R Anagnostopoulos I ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28 Nature 1999 397 263 266 9930702 10.1038/16717

Croft M Costimulation of T cells by OX40, 4–1BB, and CD27 Cytokine Growth Factor Rev 2003 14 265 273 12787564 10.1016/s1359-6101(03)00025-x

Korman AJ Peggs KS Allison JP Checkpoint blockade in cancer immunotherapy Adv. Immunol 2006 90 297 339 16730267 10.1016/S0065-2776(06)90008-X PMC1951510

Topalian SL Drake CG Pardoll DM Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity Curr. Opin. Immunol 2012 24 207 212 22236695 10.1016/j.coi.2011.12.009 PMC3319479

Drake CG Jaffee E Pardoll DM Mechanisms of immune evasion by tumors Adv. Immunol 2006 90 51 81 16730261 10.1016/S0065-2776(06)90002-9

Hodi FS O'Day SJ McDermott DF Weber RW Sosman JA Haanen JB Improved survival with ipilimumab in patients with metastatic melanoma N. Engl. J. Med 2010 363 711 723 20525992 10.1056/NEJMoa1003466 PMC3549297

Slovin SF Higano CS Hamid O Tejwani S Harzstark A Alumkal JJ Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study Ann. Oncol 2013 24 1813 1821 doi: 10.1093 23535954 10.1093/annonc/mdt107 PMC3707423

Topalian SL Hodi FS Brahmer JR Gettinger SN Smith DC McDermott DF Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N. Engl. J. Med 2012 366 2443 2454 22658127 10.1056/NEJMoa1200690 PMC3544539

Patnaik A Kang SP Tolcher AW Rasco DW Papadopoulos KP Beeram M 2012 Chicago, IL Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Presented at ASCO 2012 2 June 2012

Berger R Rotem-Yehudar R Slama G Landes S Kneller A Leiba M Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies Clin. Cancer Res 2008 14 3044 3051 18483370 10.1158/1078-0432.CCR-07-4079

Brahmer JR Tykodi SS Chow LQ Hwu W-J Topalian SL Hwu P Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N. Engl. J. Med 2012 366 2455 2465 22658128 10.1056/NEJMoa1200694 PMC3563263

Ishida Y Agata Y Shibahara K Honjo T Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death EMBO J 1992 11 3887 3895 1396582 10.1002/j.1460-2075.1992.tb05481.x PMC556898

Keir ME Butte MJ Freeman GJ Sharpe AH PD-1 and its ligands in tolerance and immunity Annu. Rev. Immunol 2008 26 677 704 18173375 10.1146/annurev.immunol.26.021607.090331 PMC10637733

Dong H Zhu G Tamada K Chen L B7-H1, a third member of the B7 family, costimulates T-cell proliferation and interleukin-10 secretion Nat. Med 1999 5 1365 1369 10581077 10.1038/70932

Latchman Y Wood CR Chernova T Chaudhary D Borde M Chernova I PD-L2 is a second ligand for PD-1 and inhibits T cell activation Nat. Immunol 2001 2 261 268 11224527 10.1038/85330

Brahmer JR Drake CG Wollner I Powderly JD Picus J Sharfman WH Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J. Clin. Oncol 2010 28 3167 3175 20516446 10.1200/JCO.2009.26.7609 PMC4834717

Patsoukis N Brown J Petkova V Liu F Li L Boussiotis VA Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation Sci. Signal 2012 5 46 10.1126/scisignal.2002796 PMC5498435 22740686

Azuma T Yao S Zhu G Flies AS Flies SJ Chen L B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells Blood 2008 111 3635 3643 18223165 10.1182/blood-2007-11-123141 PMC2275025

Probst HC McCoy K Okazaki T Honjo T van den Broek M Resting dendritic cells induce peripheral CD8+ T-cell tolerance through PD-1 and CTLA-4 Nat. Immunol 2005 6 280 286 15685176 10.1038/ni1165

Keir ME Liang SC Guleria I Latchman YE Qipo A Albacker LA Tissue expression of PD-L1 mediates peripheral T cell tolerance J. Exp. Med 2006 203 883 895 16606670 10.1084/jem.20051776 PMC2118286

Grabie N Gotsman I DaCosta R Pang H Stavrakis G Butte MJ Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart Circulation 2007 116 2062 2071 17938288 10.1161/CIRCULATIONAHA.107.709360

Barber DL Wherry EJ Masopust D Zhu B Allison JP Sharpe AH Restoring function in exhausted CD8 T cells during chronic viral infection Nature 2006 439 682 687 16382236 10.1038/nature04444

Mellman I Coukos G Dranoff G Cancer immunotherapy comes of age Nature 2011 480 480 489 22193102 10.1038/nature10673 PMC3967235

Taube JM Anders RA Young GD Xu H Sharma R McMiller TL Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape Sci. Transl. Med 2012 4 127ra37 . doi: 10.1126/scitranslmed.3003689 10.1126/scitranslmed.3003689 PMC3568523 22461641

Gajewski TF Louahed J Brichard VG Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy Cancer J 2010 16 399 403 20693853 10.1097/PPO.0b013e3181eacbd8

Thompson RH Dong H Lohse CM Leibovich BC Blute ML Cheville JC PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma Clin. Cancer Res 2007 13 1757 1761 17363529 10.1158/1078-0432.CCR-06-2599

Zhang Y Huang S Gong D Qin Y Shen Q Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer Cell. Mol. Immunol 2010 7 389 395 20514052 10.1038/cmi.2010.28 PMC4002677

Ahmadzadeh M Johnson LA Heemskerk B Wunderlich JR Dudley ME White DE Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired Blood 2009 114 1537 1544 19423728 10.1182/blood-2008-12-195792 PMC2927090

Shi F Shi M Zeng Z Qi RZ Liu ZW Zhang JY PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients Int. J. Cancer 2011 128 887 896 20473887 10.1002/ijc.25397

Zou W Chen L Inhibitory B7-family molecules in the tumour microenvironment Nat. Rev. Immunol 2008 8 467 477 18500231 10.1038/nri2326

Thompson RH Gillett MD Cheville JC Lohse CM Dong H Webster WS Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target Proc. Natl. Acad. Sci. USA 2004 101 17174 17179 15569934 10.1073/pnas.0406351101 PMC534606

Hino R Kabashima K Kato Y Yagi H Nakamura M Honjo T Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma Cancer 2010 116 1757 1766 20143437 10.1002/cncr.24899

Zeng Z Shi F Zhou L Zhang MN Chen Y Chang XJ Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma PLoS ONE 2011 6 e23621 21912640 10.1371/journal.pone.0023621 PMC3164659

Gao Q Wang XY Qiu SJ Yamato I Sho M Nakajima Y Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma Clin. Cancer Res 2009 15 971 979 19188168 10.1158/1078-0432.CCR-08-1608

Mu CY Huang JA Chen Y Chen C Zhang XG High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation Med. Oncol 2011 28 682 688 20373055 10.1007/s12032-010-9515-2

Rozali EN Hato SV Robinson BW Lake RA Lesterhuis WJ Programmed death ligand 2 in cancer-induced immune suppression Clin. Dev. Immunol 2012 2012 656340 . Abstract 656340. doi: 10.1155/2012/656340 22611421 10.1155/2012/656340 PMC3350956

Blank C Kuball J Voelkl S Wiendl H Becker B Walter B Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro Int. J. Cancer 2006 119 317 327 16482562 10.1002/ijc.21775

Wong RM Scotland RR Lau RL Wang C Korman AJ Kast WM Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs Int. Immunol 2007 19 1223 1234 17898045 10.1093/intimm/dxm091

Zhou Q Xiao H Liu Y Peng Y Hong Y Yagita H Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization J. Immunol 2010 185 5082 5092 20926790 10.4049/jimmunol.1001821 PMC3077721

Nomi T Sho M Akahori T Hamada K Kubo A Kanehiro H Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer Clin. Cancer Res 2007 13 2151 2157 17404099 10.1158/1078-0432.CCR-06-2746

Okudaira K Hokari R Tsuzuki Y Okada Y Komoto S Watanabe C Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model Int. J. Oncol 2009 35 741 749 19724910 10.3892/ijo_00000387

Iwai Y Terawaki S Honjo T PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells Int. Immunol 2005 17 133 144 15611321 10.1093/intimm/dxh194

Curran MA Montalvo W Yagita H Allison JP PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors Proc. Natl. Acad. Sci. USA 2010 107 4275 4280 20160101 10.1073/pnas.0915174107 PMC2840093

Lipson EJ Sharfman WH Drake CG Wollner I Taube JM Anders RA Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody Clin. Cancer Res 2013 19 462 468 23169436 10.1158/1078-0432.CCR-12-2625 PMC3548952

Topalian SL Brahmer JR Hodi FS McDermott DC Smith S Gettinger JM 2012 Anti-PD-1 (BMS-936558/MDX-1106/ONO-4538) in patients with advanced solid tumors: clinical activity, safety, and molecular markers . Poster presented at European Society for Medical Oncology 2012, Vienna, Austria, 1 October 2012

Iannone R Gergich K Cong C Kang P Daud A Dronca R Hollywood, CA Efficacy and safety of MK-3475 in patients with advanced melanoma. Presented at the Society for Melanoma Research 2012, 11 November 2012

Robert C Thomas L Bondarenko I O'Day S JW MD Garbe C Ipilimumab plus dacarbazine for previously untreated metastatic carcinoma N. Engl. J. Med 2011 364 2517 2526 21639810 10.1056/NEJMoa1104621

MedImmune press release 2012 MedImmune joins forces with leading cancer organizations to advance novel immunotherapy research . Available at http://pressroom.medimmune.com/press-releases/2012/10/09/medimmune-joins-forces-with-leading-cancer-organizations-to-advance-novel-immunotherapy-research (accessed 9 October 2012)

Tivol EA Borriello F Schweitzer AN Lynch WP Bluestone JA Sharpe AH Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 Immunity 1995 3 541 547 7584144 10.1016/1074-7613(95)90125-6

Waterhouse P Penninger JM Timms E Wakeham A Shahinian A Lee KP Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4 Science 1995 270 985 988 7481803 10.1126/science.270.5238.985

Nishimura H Nose M Hiai H Minato N Honjo T Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor Immunity 1999 11 141 151 10485649 10.1016/s1074-7613(00)80089-8

Qin X Liu C Zhou Y Wang G Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk/MAPK signaling pathway Cell. Mol. Biol. (Noisy-le-grand) 2010 56 Suppl OL1366 OL1372 20937224

Woo SR Turnis ME Goldberg MV Bankoti J Selby M Nirschl CJ Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immuneescape Cancer Res 2012 72 917 927 22186141 10.1158/0008-5472.CAN-11-1620 PMC3288154

Rosenblatt J Glotzbecker B Mills H Keefe W Wellenstein K Vasir B CT-011, anti-PD-1 antibody, enhances ex-vivo T cell responses to autologous dendritic/myeloma fusion vaccine developed for the treatment of multiple myeloma Blood 2009 114 781 (ASH Annual Meeting Abstracts).

Kudchadkar RR Gallenstein D Martinez AJ Yu B Weber JS Phase I trial of extended-dose anti-PD-1 antibody BMS-936558 with a multipeptide vaccine for previously treated stage IV melanoma J. Clin. Oncol 2012 30 (Suppl.; abstract 8582)

Prieto PA Yang JC Sherry RM Hughes MS Kammula US White DE Cytotoxic T lymphocyte-associated antigen 4 blockade with ipilimumab: long-term follow-up of 179 patients with metastatic melanoma J. Clin. Oncol 2010 28 15s (Suppl.): (abstract 8544)

Rini BI Stein M Shannon P Eddy S Tyler A Stephenson JJ Jr Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma Cancer 2011 117 758 767 20922784 10.1002/cncr.25639

Hammers HJ Rini BI Hudes GR Ernstoff MS Kollmannsberger CK Shen Y A phase I study of BMS-936558 plus sunitinib or pazopanib in patients with metastatic renal cell carcinoma J. Clin. Oncol 2012 30 (Suppl.; abstract TPS2614)

Gabrilovich DI Ishida T Nadaf S Ohm JE Carbone DP Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function Clin. Cancer Res 1999 5 2963 2970 10537366

Hodi FS Friedlander PA Atkins MB McDermott DF Lawrence DP Ibrahim N A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma J. Clin. Oncol 2011 29 (Suppl.; abstract 8511)

Takeuchi A Eto M Shiota M Tatsugami K Yokomizo A Kuroiwa K Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation Int. J. Oncol 2012 40 1691 1696 22344606 10.3892/ijo.2012.1368

Seliger B Massa C Rini B Ko J Finke J Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors Trends Mol. Med 2010 16 184 192 20304705 10.1016/j.molmed.2010.02.001

McDermott DF Atkins MB Immune therapy for kidney cancer: a second dawn? Semin. Oncol 2013 In press 10.1053/j.seminoncol.2013.05.008 23972713